Is developing an HIV-1 vaccine possible?

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 362-367

  Haynes, Barton F ^a,b,c   Liao, Hua Xin ^a,b   Tomaras, Georgia D ^a,c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Departments of Medicine   (United States)

^c Departments of Immunology   (United States)

^d Departments of Surgery   (United States)

Author keywords

antibodies; trials; vaccine

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; VIRUS VECTOR;

CELL CULTURE; CLINICAL TRIAL; DRUG DEVELOPMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY CELL; MUCOSA; PRIORITY JOURNAL; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION;

EID: 77955518307     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833d2e90     Document Type: Review

References (51)

1. Jones NG, DeCamp A, Gilbert P, et al. AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 2009; 27:11361140.
2. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
4. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
5. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol; 2010; 10:11-23.
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
7. Letvin NL. Virology: moving forward in HIV vaccine development. Science 2009; 326:1196-1198.
8. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190:702-706.
9. Hessell AJ, Rakasz E, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
10. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104.
11. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-954.
12. Hessell AJ, Rakasz EG, Tehrani DM, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84:1302-1313.
13. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
14. Montefiori DC, Mascola JR. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 2009;4:347-351
15. Forthal DN, Landucci G, Cole KS, et al. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006; 80:92179225.
16. Forthal DN, Landucci G, Phan TB, Becerra J. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol 2005; 79:2042-2049.
17. Tudor D, Derrien M, Diomede L, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
18. Shen R, Drelichman ER, BimczokD, et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol 2010; 184:3648-3655.
19. Marthas ML, Miller CJ. Developing a neonatal HIV vaccine: insights from macaque models of pediatric HIV/AIDS. Curr Opin HIV AIDS 2007; 2:367374.
20. Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/ SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009; 28:20-48.
21. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal SHIV challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975-5985.
22. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009; 83:791-801.
23. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-870.
24. Shen X, Parks RJ, Montefiori DC, et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009; 83:3617-3625.
25. Gray ES, Madiga MC, Moore PL, et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009; 83:1126511274.
26. Ansari AA. Autoimmunity, anergy, lentiviral immunity and disease. Autoimmun Rev 2004; 3:530-540.
27. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008; 122:12-19.
28. Chen L, Kwon YD, Zhou T, et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009; 326:11231127.
29. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 459:636-640.
30. Gorny MK, Stamatatos L, Volsky B, et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005; 79:5232-5237.
31. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
32. Wu X, Yang Z-Y, Li Y, et al. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010 [in press].
33. Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6:143-155.
34. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreac-tivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:19061908.
35. Haynes BF, Moody MA, Verkoczy L, et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59-67.
36. Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009; 106:20234-20239.
37. Ofek G, McKee K, Yang Y, et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010; 84:2955-2962.
38. Scherer EM, Leaman DP, Zwick MB, et al. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 2010; 107:1529-1534.
39. Verkoczy L, Diaz M, Holl TM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010; 107:181-186.
40. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol 2004; 2:401-413.
41. Fouts T, Godfrey K, Bobb K, et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 2002; 99:11842-11847.
42. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457:557-561.
43. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-6603.
44. Forthal DN, Landucci G, Bream J, et al. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179:7916-7923.
45. Arthos J, Cicala C, Martinelli E, et al. HIV-1 Envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nature Immunology 2008; 9:301-309.
46. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009; 106: 20877-20882.
47. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009; 83:8300-8314.
48. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
49. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.
50. Letourneau S, Im EJ, Mashishi T, et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2:e984.
51. Rolland M, Nickle DC, Mullins JI. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007; 3:e157.